Outlook for pharmaceutical stocks in 2024
At a macro level in which there is still complexity, the pharmaceutical industry is expected to continue witnessing positive business results in 2024.
Stay updated with breaking news from Genuone Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
At a macro level in which there is still complexity, the pharmaceutical industry is expected to continue witnessing positive business results in 2024.
IMP has signed a strategic cooperation agreement with Genuone Sciences Inc.
[INTERVIEW] 'Shared mobility, healthcare attractive to PEFs in ESG era' Posted : 2021-05-28 09:10 Updated : 2021-05-28 09:10 IMM Private Equity Chief Investment Officer Kim Young-ho speaks during an interview with The Korea Times at the private equity firm's head office in Seoul, May 26. Korea Times photo by Choi Won-suk This article is the last in a series of interviews with ESG experts intended to make suggestions for Korea's financial, industrial and public sectors to come up with better ESG strategies for sustainable growth. ― ED. IMM learns from SK, Shinhan to enhance sustainable in...
(Courtesy of Taihan Electric Wire Co.) The $5.4 billion fund has completed five divestitures over the past six months, estimated to have produced a combined 1 trillion won in proceeds, including both the investment principal and capital gains. The firm's aggressive divestments were in contrast to other private equity firms in Korea, which have opted to sit back until their portfolio companies achieve higher valuations with the receding of the pandemic. IMM PE was founded in 2006 by Chief Executive I.J. Song, an accountant. It focuses on Korea and Korea-related investment opportunit...